Genmab A/S (GNMSF) Projected to Announce Quarterly Earnings on Thursday

Genmab A/S (OTCMKTS:GNMSF – Get Free Report) will likely be announcing its results after the market closes on Thursday, November 5th. Analysts expect Genmab A/S to post earnings of $3.52 per share and revenue of $1.20 billion for the quarter.

Genmab A/S Stock Up 32.1%

OTCMKTS GNMSF opened at $580.00 on Thursday. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. Genmab A/S has a 52 week low of $232.34 and a 52 week high of $581.00. The firm has a market capitalization of $35.71 billion, a price-to-earnings ratio of 45.49 and a beta of 0.79. The company has a fifty day moving average of $360.98 and a two-hundred day moving average of $302.82.

About Genmab A/S

(Get Free Report)

Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.

Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity.

Featured Stories

Earnings History for Genmab A/S (OTCMKTS:GNMSF)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.